We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings
XERS

36 hedge funds and large institutions have $185M invested in Xeris Biopharma Holdings in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 2

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

20% more funds holding

Funds holding: 30 → 36 (+6)

2.15% more ownership

Funds ownership: 48.45% → 50.6% (+2.1%)

0% more capital invested

Capital invested by funds: $184M → $185M (+$805K)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
36
Holders Change
+6
Holders Change %
+20%
% of All Funds
0.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
10
Reduced
2
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$22.4M
2
BlackRock
BlackRock
New York
+$8.02M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$4.99M
4
Northern Trust
Northern Trust
Illinois
+$1.59M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.46M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$5.41M
2
BC
Broadfin Capital
New York
-$4.75M
3
FCM
Farallon Capital Management
California
-$3.03M
4
Neuberger Berman Group
Neuberger Berman Group
New York
-$2.18M
5
Millennium Management
Millennium Management
New York
-$1.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$44K +$53.8K +2,478 New
UBS Group
27
UBS Group
Switzerland
$41K +$40.3K +1,858 +399%
Citigroup
28
Citigroup
New York
$33K +$40.2K +1,850 New
SO
29
STRS Ohio
Ohio
$33K +$41.2K +1,900 New
JP Morgan Chase
30
JP Morgan Chase
New York
$27K +$33.3K +1,532 New
Legal & General Group
31
Legal & General Group
United Kingdom
$18K +$21.8K +1,005 New
Bank of America
32
Bank of America
North Carolina
$17K +$20.9K +964 New
Wells Fargo
33
Wells Fargo
California
$16K +$20.3K +935 New
AIP
34
Ameritas Investment Partners
Nebraska
$10K +$11.8K +545 New
IA
35
IFP Advisors
Florida
$4K +$4.34K +200 New
Bank of Montreal
36
Bank of Montreal
Ontario, Canada
$1K +$998 +46 New
BC
37
Broadfin Capital
New York
– -$4.75M -250,000 Closed
FCM
38
Farallon Capital Management
California
– -$3.03M -159,500 Closed
Neuberger Berman Group
39
Neuberger Berman Group
New York
– -$2.18M -115,000 Closed
Millennium Management
40
Millennium Management
New York
– -$1.9M -100,000 Closed
MWNA
41
Marshall Wace North America
New York
– -$783K -41,266 Closed
Wellington Management Group
42
Wellington Management Group
Massachusetts
– -$633K -33,333 Closed
DIM
43
DC Investments Management
Virginia
– -$563K -29,674 Closed
Goldman Sachs
44
Goldman Sachs
New York
– -$541K -28,500 Closed
Norges Bank
45
Norges Bank
Norway
– -$285K -15,000 Closed
Citadel Advisors
46
Citadel Advisors
Florida
– -$214K -11,290 Closed
Point72 Asset Management
47
Point72 Asset Management
Connecticut
– -$95K -5,000 Closed
PHK
48
Point72 Hong Kong
Hong Kong
– -$89K -4,670 Closed
CSS
49
Cubist Systematic Strategies
Connecticut
– -$12K -645 Closed
CCA
50
Catalyst Capital Advisors
New York
– -$7K -373 Closed
1
2

XERS Hedge Fund Activity: Q3 2018 in Review

36 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q3 2018, worth a combined $185M — up 0.44% from $184M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new XERS positions and 14 closed out — a net gain of 6 holders — while 10 added to existing stakes and 2 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $22.4M. The largest seller was Perceptive Advisors, cutting an estimated $5.41M.

  • 36 institutional investors held Xeris Biopharma Holdings (XERS) as of Q3 2018, up from 30 in Q2 2018.
  • Funds reported $185M of Xeris Biopharma Holdings stock for Q3 2018, up 0.44% quarter-over-quarter.
  • 20 funds opened new Xeris Biopharma Holdings positions in Q3 2018 and 14 closed out, a net change of +6 holders.
  • The largest Xeris Biopharma Holdings buyer in Q3 2018 was Fidelity Investments, an estimated $22.4M added.
  • The largest Xeris Biopharma Holdings seller in Q3 2018 was Perceptive Advisors, an estimated $5.41M sold.

Based on aggregated 13F filings for Q3 2018.